Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

690.00 6.49 −0.93%
Market cap
$257.5B
P/E
37.1×
Fwd P/E
23.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100

Thermo Fisher Scientific Inc. (TMO) Free cash flow

Alert me on Free cash flow

Thermo Fisher Scientific Inc.'s free cash flow for fiscal 2025 was $6.3B, down 13.5% from $7.3B in fiscal 2024. Over the twelve months to 30 June 2026 it was $7.4B. Over the past ten years it has ranged from $2.5B (fiscal 2015) to $7.3B (fiscal 2024); the current reading is higher than 55% of that period. Thermo Fisher Scientific Inc. ranks 1st of 52 Diagnostics & Research companies by free cash flow.

Free cash flow, annual

Embed this chart

Annual newest first

Period Free cash flow Change
FY2025 $6.3B (13.48%)
FY2024 $7.3B 4.42%
FY2023 $7.0B 1.14%
FY2022 $6.9B 1.85%
FY2021 $6.8B (0.21%)
FY2020 $6.8B 67.11%
FY2019 $4.1B 6.47%
FY2018 $3.8B 9.45%
FY2017 $3.5B 23.38%
FY2016 $2.8B 11.94%

Quarterly newest first

Period Free cash flow Change
Jun 2026 $1.7B 103.52%
Mar 2026 $825.0M (72.67%)
Dec 2025 $3.0B 64.17%
Sep 2025 $1.8B 66.27%
42 more quarters

Against its own ten years

Low $2.5B High $7.3B
Ten-year median $6.3B
Current reading's percentile 55

Free cash flow against peers

What Free cash flow is

Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.

Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)

The full definition of Free cash flow →

More on TMO